Skeletal Muscle Radiation Attenuation at C3 Predicts Survival in Head and Neck Cancer
Authors:
- Felix Barajas OrdonezFOFelix Barajas Ordonez
- Kunpeng XieKXKunpeng Xie
- André FerreiraAFAndré Ferreira
- Robert SiepmannRSRobert Siepmann
- Najiba ChargiNCNajiba Chargi
- Sven NebelungSNSven Nebelung
- Daniel TruhnDTDaniel Truhn
- Stefaan BergéSBStefaan Bergé
- Philipp BrunersPBPhilipp Bruners
- Jan EggerJEJan Egger
- Frank HölzleFHFrank Hölzle
- Markus WirthMWMarkus Wirth
Open Access
- 21 October 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 587
Abstract
Background: Sarcopenia assessed by skeletal muscle area (SMA) at the third lumbar vertebra (L3) is an established prognostic marker in many malignancies, including head and neck cancer (HNC). However, in HNC, L3 is rarely assessed. The prognostic value of myosteatosis, measured by skeletal muscle radiation attenuation (SMRA) remains largely unexplored. This study evaluated both muscle metrics at the third cervical vertebra (C3) for locoregional control (LRC) and overall survival (OS) in HNC. Methods: SMA and SMRA at C3 were quantified in CT scans of 904 HNC cases by a deep learning-based segmentation pipeline with manual verification. Cox proportional hazards models assessed associations with LRC and OS. Results: Median SMA was 36.64 cm2 (IQR: 30.12–42.44). Median SMRA was 50.77 HU (IQR: 43.04–57.39). In multivariable analysis, lower SMA (HR 1.85, 95% CI: 1.19–2.88, p ≤ 0.001) and lower SMRA (HR 1.76, 95% CI: 1.22–2.54, p < 0.001) were associated with lower LRC. For OS, lower SMA (HR 1.53, 95% CI:1.06–2.20, p = 0.02) and lower SMRA (HR 2.13, 95% CI: 1.58–2.88, p < 0.001) were associated with a worse outcome in multivariable analysis. Conclusions: Both SMRA and SMA assessed at C3 correlate with worse LRC and OS in HNC.Keywords
Funding Information
- Clinical Scientist Program of the Medical Faculty, RWTH Aachen University
- Open Access Publication Fund of RWTH
This publication has 18 references indexed in Scilit:
- The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysisBritish Journal of Cancer, 2025
- The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysisOral Oncology, 2024
- The prognostic value of pre-treatment sarcopenia in overall survival in head and neck cancer patients: a systematic reviewInternational Journal of Oral and Maxillofacial Surgery, 2024
- Longitudinal Changes in Skeletal Muscle Metabolism, Oxygen Uptake, and Myosteatosis During Cardiotoxic Treatment for Early-Stage Breast CancerThe Oncologist, 2022
- Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During ChemoradiotherapyThe Laryngoscope, 2020
- Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapyRadiotherapy and Oncology, 2020
- Myosteatosis and prognosis in cancer: Systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2020
- Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancerEuropean Journal of Cancer, 2019
- Radiomics strategies for risk assessment of tumour failure in head-and-neck cancerScientific Reports, 2017
- Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell CarcinomaJAMA Oncology, 2016